MedTrace Logo

Urine, DNA and Clinical Information Collection From Patients With Alport Nephropathy.

NCT03074357 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 68

Last updated 2018-11-09

No results posted yet for this study

Summary

This biomarker study is a follow-up to CPLATFRM2201. The goal of CBASICHR0005 is to collect another urine sample, interval clinical information, and an optional DNA sample from as many of the original 80 patients as possible. This new information will transform the data obtained in PLATFRM2201 from a cross-section to a temporal profile, which will (a) further enable the identification of biomarkers predictive of faster progression, and (b) satisfy the FDA's recommendation to perform "natural history studies" in rare diseases.

Conditions

  • Alport Nephropathy

Sponsors & Collaborators

Eligibility

Min Age
5 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-04-04
Primary Completion
2018-03-23
Completion
2018-03-23

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03074357 on ClinicalTrials.gov